- The report reveals double digit growth of therapeutic antibody sales, while therapeutic proteins contribute only 15% to the biologics market of nearly US$ 380 bln in 2025.
- Increasing adoption of novel biologic drug modalities (RNA, CAR-T, DNA) by major pharmaceutical companies.
- Only seven companies with biosimilar sales of more than US$ 1 bln in 2025.
BARCELONA, Spain I March 10, 2026 I La Merie Publishing announced the publication of the biologics market report for the calendar year 2025 covering individual sales data for more than 400 biologic products. The report “2025 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA” analyzes market volume and growth rates of innovator, branded therapeutic antibodies and proteins and biosimilars of antibodies and proteins with loss of exclusivity. The report also describes the market growth of the novel biologic modalities gene & cell therapy and RNA therapeutics.
The global market of recombinant innovator, branded therapeutics antibodies and proteins continued its double digit growth and reached nearly US$ 380 bln in the calendar year 2025. This increase was mainly driven by the strong growth of anti-inflammatory and cancer antibodies despite the further decline of sales of anti-TNF antibodies (-23%) due to biosimilar competition. The new antibody drug modalities antibody-drug conjugates (ADC) and bispecific antibodies still contribute less than 10% to the total antibody market, but their share of the antibody market is growing year by year with the entry of new products.
The entry of new biosimilar antibodies into the market fuels the biosimilar antibody business with strong growth perspectives and space for consolidation as well as for strengthening marketing muscles of biosimilar manufacturers.
The new biologic drug modalities RNA, DNA and Cells (especially CAR-T) still are at their infancy with a market size equivalent to 5% of the antibody and protein biologics market in 2025, but these modalities show growth rates between 40% and 50% in 2025 compared with the previous year. Major pharmaceutical companies increasingly adopt the new biologic drug modalities into their technology and product portfolio as reflected by by a still minor contribution to total company sales.
The ranking list of blockbuster biologics, i.e. antibodies and proteins with sales of more than US$ 1 bln, grew to 80 biologic products in 2025. Of the TOP 30 companies with innovator biologic products, 12 had sales of therapeutic antibodies and proteins of more than US$ 10 bln in 2025 with Roche clearly leading the field (> US$ 53 bln).
Methodology
The report covers sales data of more than 400 commercialized biologics (innovator antibodies and proteins). Sales data were obtained from company disclosures and refer to innovative branded products as well as biosimilars and other biologics (gene & cell therapy, antisense, siRNA). All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of January 29, 2026. Cut-off date for inclusion into the report was March 05, 2026. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates are presented as reported, except in few cases at constant exchange rates. All sales data refer to the calendar year 2025. Financial years differing from the calendar year were recalculated to the calendar year 2025 by summing up the respective calendar year quarterly sales.
The report 2025 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2025-sales-of-therapeutic-antibodies-proteins-biosimilars-gene-cell-therapy-and-therapeutic-rna-copy/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.
Among La Merie Publishing’s services are the pre-scoped evaluation of customer-selected targets for drug discovery: Target Evaluation for Drug Discovery: Pre-Scoped Premium Evaluation and the pre-scoped review of the pipeline of immunotherapies against customer-selected targets: Pipeline Review of Customer-Selected Targeted Immunotherapies: Pre-Scoped Competitor Analysis.
SOURCE: La Merie Publishing